Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 169

1.

Posttransplant reduction in preexisting donor-specific antibody levels after belatacept- versus cyclosporine-based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT-EXT.

Bray RA, Gebel HM, Townsend R, Roberts ME, Polinsky M, Yang L, Meier-Kriesche HU, Larsen CP.

Am J Transplant. 2018 Jul;18(7):1774-1782. doi: 10.1111/ajt.14738. Epub 2018 Apr 17.

2.

De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies.

Bray RA, Gebel HM, Townsend R, Roberts ME, Polinsky M, Yang L, Meier-Kriesche HU, Larsen CP.

Am J Transplant. 2018 Jul;18(7):1783-1789. doi: 10.1111/ajt.14721. Epub 2018 Apr 2.

3.

Ten-year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4-weekly or 8-weekly.

Vincenti F, Blancho G, Durrbach A, Grannas G, Grinyó J, Meier-Kriesche HU, Polinsky M, Yang L, Larsen CP.

Am J Transplant. 2017 Dec;17(12):3219-3227. doi: 10.1111/ajt.14452. Epub 2017 Sep 5.

4.

Efficacy and Safety Outcomes of Extended Criteria Donor Kidneys by Subtype: Subgroup Analysis of BENEFIT-EXT at 7 Years After Transplant.

Florman S, Becker T, Bresnahan B, Chevaile-Ramos A, Carvalho D, Grannas G, Muehlbacher F, O'Connell PJ, Meier-Kriesche HU, Larsen CP.

Am J Transplant. 2017 Jan;17(1):180-190. doi: 10.1111/ajt.13886. Epub 2016 Jul 12.

5.

Long-Term Outcomes in Belatacept- Versus Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT-EXT, a Phase III Randomized Study.

Durrbach A, Pestana JM, Florman S, Del Carmen Rial M, Rostaing L, Kuypers D, Matas A, Wekerle T, Polinsky M, Meier-Kriesche HU, Munier S, Grinyó JM.

Am J Transplant. 2016 Nov;16(11):3192-3201. doi: 10.1111/ajt.13830. Epub 2016 Jun 9.

6.

Belatacept and Long-Term Outcomes in Kidney Transplantation.

Vincenti F, Rostaing L, Grinyo J, Rice K, Steinberg S, Gaite L, Moal MC, Mondragon-Ramirez GA, Kothari J, Polinsky MS, Meier-Kriesche HU, Munier S, Larsen CP.

N Engl J Med. 2016 Jan 28;374(4):333-43. doi: 10.1056/NEJMoa1506027. Erratum in: N Engl J Med. 2016 Feb 18;374(7):698.

7.

Lack of significant improvements in long-term allograft survival in pediatric solid organ transplantation: A US national registry analysis.

Dharnidharka VR, Lamb KE, Zheng J, Schechtman KB, Meier-Kriesche HU.

Pediatr Transplant. 2015 Aug;19(5):477-83. doi: 10.1111/petr.12465. Epub 2015 Apr 1.

PMID:
25832769
8.

Across all solid organs, adolescent age recipients have worse transplant organ survival than younger age children: A US national registry analysis.

Dharnidharka VR, Lamb KE, Zheng J, Schechtman KB, Meier-Kriesche HU.

Pediatr Transplant. 2015 Aug;19(5):471-6. doi: 10.1111/petr.12464. Epub 2015 Apr 1.

PMID:
25832588
9.

Prolonged immunosuppression preserves nonsensitization status after kidney transplant failure.

Casey MJ, Wen X, Kayler LK, Aiyer R, Scornik JC, Meier-Kriesche HU.

Transplantation. 2014 Aug 15;98(3):306-11. doi: 10.1097/TP.0000000000000057.

10.

Clinical characteristics and outcomes in 303 HIV-infected patients with invasive fungal infections: data from the Prospective Antifungal Therapy Alliance registry, a multicenter, observational study.

Marukutira T, Huprikar S, Azie N, Quan SP, Meier-Kriesche HU, Horn DL.

HIV AIDS (Auckl). 2014 Mar 13;6:39-47. doi: 10.2147/HIV.S53910. eCollection 2014.

11.

Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release/MMF, tacrolimus/MMF, and cyclosporine/MMF in de novo kidney transplant recipients.

Silva HT Jr, Yang HC, Meier-Kriesche HU, Croy R, Holman J, Fitzsimmons WE, First MR.

Transplantation. 2014 Mar 27;97(6):636-41. doi: 10.1097/01.TP.0000437669.93963.8E.

12.

Obesity and kidney transplantation.

Srinivas TR, Meier-Kriesche HU.

Semin Nephrol. 2013 Jan;33(1):34-43. doi: 10.1016/j.semnephrol.2012.12.007. Review.

PMID:
23374892
13.

Best allograft survival from share-35 kidney donors occurs in middle-aged adults and young children-an analysis of OPTN data.

Moudgil A, Dharnidharka VR, Lamb KE, Meier-Kriesche HU.

Transplantation. 2013 Jan 27;95(2):319-25. doi: 10.1097/TP.0b013e3182719203.

PMID:
23154211
14.

Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance®) registry, 2004-2008.

Pfaller M, Neofytos D, Diekema D, Azie N, Meier-Kriesche HU, Quan SP, Horn D.

Diagn Microbiol Infect Dis. 2012 Dec;74(4):323-31. doi: 10.1016/j.diagmicrobio.2012.10.003. Epub 2012 Oct 25. Review.

PMID:
23102556
15.

Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry.

Steinbach WJ, Marr KA, Anaissie EJ, Azie N, Quan SP, Meier-Kriesche HU, Apewokin S, Horn DL.

J Infect. 2012 Nov;65(5):453-64. doi: 10.1016/j.jinf.2012.08.003. Epub 2012 Aug 13.

PMID:
22898389
16.

Pulsatile pump decreases risk of delayed graft function in kidneys donated after cardiac death.

Lodhi SA, Lamb KE, Uddin I, Meier-Kriesche HU.

Am J Transplant. 2012 Oct;12(10):2774-80. doi: 10.1111/j.1600-6143.2012.04179.x. Epub 2012 Jul 23.

17.

The PATH (Prospective Antifungal Therapy) Alliance® registry and invasive fungal infections: update 2012.

Azie N, Neofytos D, Pfaller M, Meier-Kriesche HU, Quan SP, Horn D.

Diagn Microbiol Infect Dis. 2012 Aug;73(4):293-300. doi: 10.1016/j.diagmicrobio.2012.06.012. Review.

PMID:
22789847
18.

Associations between EBV serostatus and organ transplant type in PTLD risk: an analysis of the SRTR National Registry Data in the United States.

Dharnidharka VR, Lamb KE, Gregg JA, Meier-Kriesche HU.

Am J Transplant. 2012 Apr;12(4):976-83. doi: 10.1111/j.1600-6143.2011.03893.x. Epub 2012 Jan 6.

19.

Improving long-term outcomes for transplant patients: making the case for long-term disease-specific and multidisciplinary research.

Lodhi SA, Lamb KE, Meier-Kriesche HU.

Am J Transplant. 2011 Oct;11(10):2264-5. doi: 10.1111/j.1600-6143.2011.03713.x. No abstract available.

20.

The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation.

Busque S, Cantarovich M, Mulgaonkar S, Gaston R, Gaber AO, Mayo PR, Ling S, Huizinga RB, Meier-Kriesche HU; PROMISE Investigators.

Am J Transplant. 2011 Dec;11(12):2675-84. doi: 10.1111/j.1600-6143.2011.03763.x. Epub 2011 Sep 22.

21.

Calcineurin inhibitors in kidney transplantation: friend or foe?

Casey MJ, Meier-Kriesche HU.

Curr Opin Nephrol Hypertens. 2011 Nov;20(6):610-5. doi: 10.1097/MNH.0b013e32834b4343. Review.

PMID:
21885969
22.

Blood transfusions in organ transplant patients: mechanisms of sensitization and implications for prevention.

Scornik JC, Meier-Kriesche HU.

Am J Transplant. 2011 Sep;11(9):1785-91. doi: 10.1111/j.1600-6143.2011.03705.x. Epub 2011 Aug 22. Review.

23.

Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study.

Claes K, Meier-Kriesche HU, Schold JD, Vanrenterghem Y, Halloran PF, Ekberg H.

Nephrol Dial Transplant. 2012 Feb;27(2):850-7. doi: 10.1093/ndt/gfr238. Epub 2011 May 26.

PMID:
21617197
24.

Barriers to evaluation and wait listing for kidney transplantation.

Schold JD, Gregg JA, Harman JS, Hall AG, Patton PR, Meier-Kriesche HU.

Clin J Am Soc Nephrol. 2011 Jul;6(7):1760-7. doi: 10.2215/CJN.08620910. Epub 2011 May 19.

25.

The search for CNI-free immunosuppression: no free lunch.

Meier-Kriesche HU, Kaplan B.

Am J Transplant. 2011 Jul;11(7):1355-6. doi: 10.1111/j.1600-6143.2011.03541.x. Epub 2011 May 12. No abstract available.

26.

Solid organ allograft survival improvement in the United States: the long-term does not mirror the dramatic short-term success.

Lodhi SA, Lamb KE, Meier-Kriesche HU.

Am J Transplant. 2011 Jun;11(6):1226-35. doi: 10.1111/j.1600-6143.2011.03539.x. Epub 2011 May 12.

27.

Mycophenolate mofetil initiation in renal transplant patients at different times posttransplantation: the TranCept Switch study.

Meier-Kriesche HU, Merville P, Tedesco-Silva H, Heemann U, Kes P, Haller H, Rostaing L, Gafner N, Bernasconi C.

Transplantation. 2011 May 15;91(9):984-90. doi: 10.1097/TP.0b013e3182130966.

PMID:
21464796
28.

Kidney allograft survival: the long and short of it.

Lodhi SA, Meier-Kriesche HU.

Nephrol Dial Transplant. 2011 Jan;26(1):15-7. doi: 10.1093/ndt/gfq730. No abstract available.

PMID:
21177522
29.

The noninferiority trial: don't don't do it.

Srinivas TR, Kaplan B, Meier-Kriesche HU.

Am J Transplant. 2010 Dec;10(12):2571-3. doi: 10.1111/j.1600-6143.2010.03323.x. Epub 2010 Nov 18. No abstract available.

30.

Long-term renal allograft survival in the United States: a critical reappraisal.

Lamb KE, Lodhi S, Meier-Kriesche HU.

Am J Transplant. 2011 Mar;11(3):450-62. doi: 10.1111/j.1600-6143.2010.03283.x. Epub 2010 Oct 25.

31.

Use of intravenous immune globulin and rituximab for desensitization of highly human leukocyte antigen-sensitized patients awaiting kidney transplantation.

Rehman S, Meier-Kriesche HU, Scornik J.

Transplantation. 2010 Oct 27;90(8):932; author reply 932-3. doi: 10.1097/TP.0b013e3181f15456. No abstract available.

PMID:
20962612
32.

Association between admission hyperglycemia and length of stay after renal transplantation.

Tewari S, Kathuria A, Meier-Kriesche HU, Lansang MC.

Endocr Pract. 2010 Sep-Oct;16(5):805-9. doi: 10.4158/EP09290.OR.

PMID:
20439248
33.

Effect of IVIG administration on complement activation and HLA antibody levels.

Machimoto T, Guerra G, Burke G, Fricker FJ, Colona J, Ruiz P, Meier-Kriesche HU, Scornik J.

Transpl Int. 2010 Oct;23(10):1015-22. doi: 10.1111/j.1432-2277.2010.01088.x.

34.

Mycophenolic acid exposure in high- and low-weight renal transplant patients after dosing with mycophenolate mofetil in the Opticept trial.

Kaplan B, Gaston RS, Meier-Kriesche HU, Bloom RD, Shaw LM.

Ther Drug Monit. 2010 Apr;32(2):224-7. doi: 10.1097/FTD.0b013e3181d18baa.

PMID:
20216117
35.

Elevated incidence of posttransplant erythrocytosis after simultaneous pancreas kidney transplantation.

Guerra G, Indahyung R, Bucci CM, Schold JD, Magliocca JF, Meier-Kriesche HU.

Am J Transplant. 2010 Apr;10(4):938-42. doi: 10.1111/j.1600-6143.2010.03012.x. Epub 2010 Feb 10.

36.

The success of continued steroid avoidance after kidney transplantation in the US.

Schold JD, Santos A, Rehman S, Magliocca J, Meier-Kriesche HU.

Am J Transplant. 2009 Dec;9(12):2768-76. doi: 10.1111/j.1600-6143.2009.02838.x. Epub 2009 Oct 21.

37.

Uric acid levels have no significant effect on renal function in adult renal transplant recipients: evidence from the symphony study.

Meier-Kriesche HU, Schold JD, Vanrenterghem Y, Halloran PF, Ekberg H.

Clin J Am Soc Nephrol. 2009 Oct;4(10):1655-60. doi: 10.2215/CJN.02700409. Epub 2009 Aug 27.

38.

A lifetime versus a graft life approach redefines the importance of HLA matching in kidney transplant patients.

Meier-Kriesche HU, Scornik JC, Susskind B, Rehman S, Schold JD.

Transplantation. 2009 Jul 15;88(1):23-9. doi: 10.1097/TP.0b013e3181a9ec89.

PMID:
19584676
39.

Comparable barriers to access to kidney transplantation across national lines.

Schold JD, Meier-Kriesche HU.

Transplantation. 2009 Jul 15;88(1):21-2. doi: 10.1097/TP.0b013e3181a9eabe. No abstract available.

PMID:
19584675
40.

Half of kidney transplant candidates who are older than 60 years now placed on the waiting list will die before receiving a deceased-donor transplant.

Schold J, Srinivas TR, Sehgal AR, Meier-Kriesche HU.

Clin J Am Soc Nephrol. 2009 Jul;4(7):1239-45. doi: 10.2215/CJN.01280209. Epub 2009 Jun 18.

41.

Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial.

Gaston RS, Kaplan B, Shah T, Cibrik D, Shaw LM, Angelis M, Mulgaonkar S, Meier-Kriesche HU, Patel D, Bloom RD.

Am J Transplant. 2009 Jul;9(7):1607-19. doi: 10.1111/j.1600-6143.2009.02668.x. Epub 2009 May 20.

42.

The AST's perspective on the proposed kidney allocation system.

Murphy B, Vincenti F, Meier-Kriesche HU.

Am J Transplant. 2009 Jul;9(7):1500. doi: 10.1111/j.1600-6143.2009.02674.x. Epub 2009 May 20. No abstract available.

43.

Effects of blood transfusions given after renal transplantation.

Scornik JC, Schold JD, Bucci M, Meier-Kriesche HU.

Transplantation. 2009 May 15;87(9):1381-6. doi: 10.1097/TP.0b013e3181a24b96.

PMID:
19424040
44.

Treatment for BK virus: incidence, risk factors and outcomes for kidney transplant recipients in the United States.

Schold JD, Rehman S, Kayle LK, Magliocca J, Srinivas TR, Meier-Kriesche HU.

Transpl Int. 2009 Jun;22(6):626-34. doi: 10.1111/j.1432-2277.2009.00842.x. Epub 2009 Feb 2. Erratum in: Transpl Int. 2009 Jul;22(7):770. Kayler, Liise K [corrected to Kayle, Liise K].

45.

The pivotal impact of center characteristics on survival of candidates listed for deceased donor kidney transplantation.

Schold JD, Harman JS, Chumbler NR, Duncan RP, Meier-Kriesche HU.

Med Care. 2009 Feb;47(2):146-53. doi: 10.1097/MLR.0b013e31818475c9.

PMID:
19169114
46.

The relationship between circulating natural killer cells after reduced intensity conditioning hematopoietic stem cell transplantation and relapse-free survival and graft-versus-host disease.

Dunbar EM, Buzzeo MP, Levine JB, Schold JD, Meier-Kriesche HU, Reddy V.

Haematologica. 2008 Dec;93(12):1852-8. doi: 10.3324/haematol.13033. Epub 2008 Oct 22.

47.

Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients.

Kasiske BL, de Mattos A, Flechner SM, Gallon L, Meier-Kriesche HU, Weir MR, Wilkinson A.

Am J Transplant. 2008 Jul;8(7):1384-92. doi: 10.1111/j.1600-6143.2008.02272.x. Review.

48.

Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result.

Srinivas TR, Meier-Kriesche HU.

Clin J Am Soc Nephrol. 2008 Mar;3 Suppl 2:S101-16. doi: 10.2215/CJN.03510807. Review.

49.

Kidney-transplant rejection and anti-MICA antibodies.

Dragun D, Scornik J, Meier-Kriesche HU.

N Engl J Med. 2008 Jan 10;358(2):196; author reply 196. No abstract available.

PMID:
18193529
50.

The association of candidate mortality rates with kidney transplant outcomes and center performance evaluations.

Schold JD, Srinivas TR, Howard RJ, Jamieson IR, Meier-Kriesche HU.

Transplantation. 2008 Jan 15;85(1):1-6. doi: 10.1097/01.tp.0000297372.51408.c2.

PMID:
18192903

Supplemental Content

Loading ...
Support Center